We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Countdown to Neogen (NEOG) Q3 Earnings: Wall Street Forecasts for Key Metrics
Read MoreHide Full Article
In its upcoming report, Neogen (NEOG - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.04 per share, reflecting a decline of 60% compared to the same period last year. Revenues are forecasted to be $204.46 million, representing a year-over-year decrease of 7.5%.
The consensus EPS estimate for the quarter has undergone a downward revision of 8.3% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
With that in mind, let's delve into the average projections of some Neogen metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts predict that the 'Revenues- Animal Safety' will reach $56.02 million. The estimate indicates a change of -17.9% from the prior-year quarter.
It is projected by analysts that the 'Revenues- Food Safety' will reach $148.11 million. The estimate indicates a change of -3% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenues- Food Safety- Indicator Testing, Culture Media & Other' should come in at $81.18 million. The estimate points to a change of +4.4% from the year-ago quarter.
Analysts' assessment points toward 'Revenues- Animal Safety- Veterinary Instruments & Disposables' reaching $15.38 million. The estimate indicates a year-over-year change of -0.2%.
Analysts expect 'Revenues- Animal Safety- Animal Care & Other' to come in at $9.61 million. The estimate suggests a change of -8.5% year over year.
The combined assessment of analysts suggests that 'Revenues- Food Safety- Natural Toxins & Allergens' will likely reach $17.65 million. The estimate indicates a year-over-year change of +0.3%.
The average prediction of analysts places 'Revenues- Animal Safety- Genomics Services' at $3.34 million. The estimate suggests a change of -80.4% year over year.
The consensus among analysts is that 'Revenues- Food Safety- Genomics Services' will reach $11.34 million. The estimate suggests a change of +99% year over year.
The consensus estimate for 'Revenues- Food Safety- Biosecurity Products' stands at $4.29 million. The estimate points to a change of -63.7% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenues- Food Safety- Bacterial & General Sanitation' should arrive at $40.39 million. The estimate indicates a change of +1.3% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenues- Animal Safety- Biosecurity Products' of $18.96 million. The estimate indicates a change of -20.4% from the prior-year quarter.
Shares of Neogen have demonstrated returns of -12% over the past month compared to the Zacks S&P 500 composite's -4.2% change. With a Zacks Rank #4 (Sell), NEOG is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Countdown to Neogen (NEOG) Q3 Earnings: Wall Street Forecasts for Key Metrics
In its upcoming report, Neogen (NEOG - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.04 per share, reflecting a decline of 60% compared to the same period last year. Revenues are forecasted to be $204.46 million, representing a year-over-year decrease of 7.5%.
The consensus EPS estimate for the quarter has undergone a downward revision of 8.3% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
With that in mind, let's delve into the average projections of some Neogen metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts predict that the 'Revenues- Animal Safety' will reach $56.02 million. The estimate indicates a change of -17.9% from the prior-year quarter.
It is projected by analysts that the 'Revenues- Food Safety' will reach $148.11 million. The estimate indicates a change of -3% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenues- Food Safety- Indicator Testing, Culture Media & Other' should come in at $81.18 million. The estimate points to a change of +4.4% from the year-ago quarter.
Analysts' assessment points toward 'Revenues- Animal Safety- Veterinary Instruments & Disposables' reaching $15.38 million. The estimate indicates a year-over-year change of -0.2%.
Analysts expect 'Revenues- Animal Safety- Animal Care & Other' to come in at $9.61 million. The estimate suggests a change of -8.5% year over year.
The combined assessment of analysts suggests that 'Revenues- Food Safety- Natural Toxins & Allergens' will likely reach $17.65 million. The estimate indicates a year-over-year change of +0.3%.
The average prediction of analysts places 'Revenues- Animal Safety- Genomics Services' at $3.34 million. The estimate suggests a change of -80.4% year over year.
The consensus among analysts is that 'Revenues- Food Safety- Genomics Services' will reach $11.34 million. The estimate suggests a change of +99% year over year.
The consensus estimate for 'Revenues- Food Safety- Biosecurity Products' stands at $4.29 million. The estimate points to a change of -63.7% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenues- Food Safety- Bacterial & General Sanitation' should arrive at $40.39 million. The estimate indicates a change of +1.3% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenues- Animal Safety- Biosecurity Products' of $18.96 million. The estimate indicates a change of -20.4% from the prior-year quarter.
View all Key Company Metrics for Neogen here>>>Shares of Neogen have demonstrated returns of -12% over the past month compared to the Zacks S&P 500 composite's -4.2% change. With a Zacks Rank #4 (Sell), NEOG is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .